Compare Recursion Pharmaceuticals Inc (RXRX) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Vanguard Information Technology Index Fund ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while Vanguard Information Technology Index Fund ETF trades at $116.09. The key difference: Vanguard Information Technology Index Fund ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | VGT | |
|---|---|---|
Market Cap | $1.53B | — |
Sector | Health | — |
52-Week High | $6.79 | $125.77 |
52-Week Low | $2.84 | $83.59 |
Enterprise Value | $946.50M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
VGT trades at $113.23, showing minimal daily movement with a 0.11% gain. Technical indicators signal a bearish trend with moving averages and overall signals pointing downward, though oscillators remain neutral. The ETF recently completed a 1:8 stock split and has a small dividend scheduled for June 2026. Recent news highlights strong historical performance but notes current semiconductor sector volatility affecting tech ETFs.
The outlook for VGT remains tied to technology sector momentum, particularly AI and semiconductor growth. Key risks include sector concentration and valuation concerns after recent run-ups. Analyst sentiment appears mixed, balancing strong long-term track record against near-term technical weakness and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →
